Maxim Group Lowers Tenon Medical (NASDAQ:TNON) Price Target to $8.00

Tenon Medical (NASDAQ:TNON) had its price objective reduced by Maxim Group from $22.00 to $8.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Tenon Medical in a research note on Wednesday, August 14th.

Tenon Medical Trading Down 8.1 %

Shares of NASDAQ TNON opened at $2.49 on Friday. Tenon Medical has a 12 month low of $2.46 and a 12 month high of $20.00. The company has a 50 day simple moving average of $4.03 and a two-hundred day simple moving average of $1.89. The stock has a market cap of $1.27 million, a price-to-earnings ratio of -0.09 and a beta of 2.15.

Tenon Medical Company Profile

Tenon Medical, Inc, a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.